RX.HA.25mg+ is a Be Ceuticals hyaluronic acid soft-tissue filler supplied in a two-by-2 ml presentation and positioned for facial volume restoration and deep depressions.

The manufacturer brochure and a Lebanese Ministry of Public Health record support the product identity and Swiss manufacturer, but patient suitability and injection planning remain medical decisions for an appropriately licensed practitioner.

Catalogue visual: RX.HA.25mg+ (Intense Volume) from the NEES Medical product catalogue. Packaging appearance alone does not establish authenticity; verify the supplied batch, expiry, seals and traceability documents.

What it is

Be Ceuticals identifies RX.HA.25mg+ as the Intense Volume member of its professional RX.HA range. Public records describe a hyaluronic acid injectable gel supplied as two pre-filled 2 ml syringes; public sources differ slightly between the family name of 25mg+ and a brochure specification of 24 mg/ml, so the physical instructions for the supplied lot are the final reference. The product is intended for professional aesthetic practice, not self-use.

Market position and alternatives

RX.HA.25mg+ sits in the structural HA-filler segment, where buyers compare rheology, syringe volume, labelled treatment plane, traceability and practitioner familiarity rather than concentration alone.

Potential advantages

• The official range provides a clear product hierarchy for matching gel selection to the intended correction.
• The two-by-2 ml pack offers more total material than many one-syringe facial filler presentations.
• Hyaluronic acid fillers have an established clinical category and a substantial practitioner safety literature.
• The product and Swiss manufacturer appear in a government health-record document, supporting identity verification.

Limitations and buying considerations

• No public head-to-head trial was located proving that RX.HA.25mg+ outperforms other structural HA fillers.
• Filler concentration alone does not predict lifting capacity, tissue integration, duration or complication risk.
• All dermal fillers can cause adverse events, including rare vascular occlusion, tissue injury, visual loss or stroke.
• The difference between public 24 mg/ml and 25 mg/ml descriptions must be resolved from the current lot label and instructions.

Quality and authenticity checklist

• Match the RX.HA.25mg+ Intense Volume name and two-by-2 ml presentation to current Be Ceuticals documentation.
• Verify intact seals and matching lot, expiry and manufacturer information on the carton and both syringes.
• Confirm the labelled hyaluronic acid concentration and storage range on the supplied lot rather than relying on reseller copy.
• Retain the supplier invoice and lot photographs and reject loose, damaged, relabelled or previously opened syringes.

Price and availability in Pakistan

The current RX.HA.25mg+ price in Pakistan is available by quotation from NEES Medical; the live catalogue does not publish a verified numeric PKR price. Quotes may vary with stock, import cost, order quantity and delivery city, and clinics should compare the exact two-by-2 ml presentation with complete traceability.

Sources and further reading

• Be Ceuticals — RX.HA Professional Line Brochure
• Lebanon Ministry of Public Health — Technical Committee Decisions
• US FDA — Dermal Fillers (Soft Tissue Fillers)

View the RX.HA.25mg+ (Intense Volume) catalogue page or request current pricing and availability.